Dachaigh › Ailseachadh an Ae (Carcinoma Hepatocellular) › Tennessee › Nashville
Sgrùdaidhean clionaigeach Ailseachadh an Ae (Carcinoma Hepatocellular) ann an Nashville, TN
Tha 10 sgrùdaidhean airson Ailseachadh an Ae (Carcinoma Hepatocellular) a’ lorg phàirtichean aig làraichean ann agus timcheall air Nashville (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
A’ fastadhÌre 1
- SCRI Oncology Partners, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A’ fastadhÌre 1
- Exelixis Clinical Site #3, Nashville
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
A’ fastadhÌre 1/2
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Scri Oncology Partners, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
A’ fastadhÌre 1/2
- SCRI Oncology Partners, Nashville
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
A’ fastadhÌre 2
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
A’ fastadhÌre 1
- HCA Research Institute, LLC, Brentwood · 9 mìle air falbh
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Nashville
Sgrùdaidhean Ailseachadh an Ae (Carcinoma Hepatocellular) ann am bailtean eile
- Houston, TX31 sgrùdaidhean
- New York City, NY24 sgrùdaidhean
- Dallas, TX19 sgrùdaidhean
- Los Angeles, CA19 sgrùdaidhean
- Boston, MA18 sgrùdaidhean
- Cleveland, OH18 sgrùdaidhean
- Chicago, IL16 sgrùdaidhean
- Philadelphia, PA16 sgrùdaidhean
- Pittsburgh, PA15 sgrùdaidhean
- San Francisco, CA14 sgrùdaidhean
- Orange, CA14 sgrùdaidhean
- Jacksonville, FL14 sgrùdaidhean
Sgrùdaidhean eile ann an Nashville
- Aillse Sgamhain Neo-chealla-beag97 sgrùdaidhean
- Aillse a' bhroilleach81 sgrùdaidhean
- Ailse metastatach70 sgrùdaidhean
- Aillse colorectal69 sgrùdaidhean
- Aillse (gach seòrsa)65 sgrùdaidhean
- Cancer Ovarian49 sgrùdaidhean
- Aillse Prostata43 sgrùdaidhean
- Ailseachadh nan Sgamhan40 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil39 sgrùdaidhean
- Cancer Pancreatic39 sgrùdaidhean
- Ailse Endometrial38 sgrùdaidhean
- Melanoma33 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.